Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi‐eligible countries

The human papillomavirus (HPV) vaccines may provide some level of cross‐protection against high‐risk HPV genotypes not directly targeted by the vaccines. We evaluated the long‐term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vacc...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of cancer Vol. 148; no. 4; pp. 932 - 940
Main Authors:	Burger, Emily A., Portnoy, Allison, Campos, Nicole G., Sy, Stephen, Regan, Catherine, Kim, Jane J.
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 15.02.2021 Wiley Subscription Services, Inc
Subjects:	Cancer Cancer vaccines Cervical cancer Cervix GDP Genotypes Gross Domestic Product Human papillomavirus Immunization low‐ and middle‐income countries Medical research Vaccines low- and middle-income countries vaccines cervical cancer human papillomavirus
ISSN:	0020-7136, 1097-0215, 1097-0215
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	The human papillomavirus (HPV) vaccines may provide some level of cross‐protection against high‐risk HPV genotypes not directly targeted by the vaccines. We evaluated the long‐term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vaccine in the context of 48 Gavi‐eligible countries. We used a multi‐modeling approach to compare the bivalent with or without cross‐protection and the nonavalent HPV vaccine. The optimal, that is, most cost‐effective, vaccine was the vaccine with an incremental cost‐effectiveness ratio below the per‐capita gross domestic product (GDP) for each country. By 2100 and assuming 70% HPV vaccination coverage, a bivalent vaccine without cross‐protection, a bivalent vaccine with favorable cross‐protection and the nonavalent vaccine were projected to avert 14.9, 17.2 and 18.5 million cumulative cases of cervical cancer across all 48 Gavi‐eligible countries, respectively. The relative value of the bivalent vaccine compared to the nonavalent vaccine increased assuming a bivalent vaccine conferred high cross‐protection. For example, assuming a cost‐effectiveness threshold of per‐capita GDP, the nonavalent vaccine was optimal in 83% (n = 40) of countries if the bivalent vaccine did not confer cross‐protection; however, the proportion of countries decreased to 63% (n = 30) if the bivalent vaccine conferred high cross‐protection. For lower cost‐effectiveness thresholds, the bivalent vaccine was optimal in a greater proportion of countries, under both cross‐protection assumptions. Although the nonavalent vaccine is projected to avert more cases of cervical cancer, the bivalent vaccine with favorable cross‐protection can prevent a considerable number of cases and would be considered a high‐value vaccine for many Gavi‐eligible countries. What's new? The nonavalent human papillomavirus (HPV) vaccine has generally been considered to confer enough additional benefit to warrant a higher price. However, most previous analyses did not fully consider possible cross‐protection by the bivalent vaccine and focused on high‐income countries. This study projected the health and economic tradeoffs of using either vaccine in low‐ and middle‐income countries, incorporating recent data on bivalent cross‐protection and Gavi‐negotiated vaccine prices. Although the nonavalent HPV vaccine was projected to avert more cases of cervical cancer, the bivalent vaccine, with an assumed high and long‐lasting cross‐protective efficacy, would be cost‐effective for nearly half of Gavi‐eligible countries.
AbstractList	The human papillomavirus (HPV) vaccines may provide some level of cross‐protection against high‐risk HPV genotypes not directly targeted by the vaccines. We evaluated the long‐term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vaccine in the context of 48 Gavi‐eligible countries. We used a multi‐modeling approach to compare the bivalent with or without cross‐protection and the nonavalent HPV vaccine. The optimal, that is, most cost‐effective, vaccine was the vaccine with an incremental cost‐effectiveness ratio below the per‐capita gross domestic product (GDP) for each country. By 2100 and assuming 70% HPV vaccination coverage, a bivalent vaccine without cross‐protection, a bivalent vaccine with favorable cross‐protection and the nonavalent vaccine were projected to avert 14.9, 17.2 and 18.5 million cumulative cases of cervical cancer across all 48 Gavi‐eligible countries, respectively. The relative value of the bivalent vaccine compared to the nonavalent vaccine increased assuming a bivalent vaccine conferred high cross‐protection. For example, assuming a cost‐effectiveness threshold of per‐capita GDP, the nonavalent vaccine was optimal in 83% (n = 40) of countries if the bivalent vaccine did not confer cross‐protection; however, the proportion of countries decreased to 63% (n = 30) if the bivalent vaccine conferred high cross‐protection. For lower cost‐effectiveness thresholds, the bivalent vaccine was optimal in a greater proportion of countries, under both cross‐protection assumptions. Although the nonavalent vaccine is projected to avert more cases of cervical cancer, the bivalent vaccine with favorable cross‐protection can prevent a considerable number of cases and would be considered a high‐value vaccine for many Gavi‐eligible countries. What's new? The nonavalent human papillomavirus (HPV) vaccine has generally been considered to confer enough additional benefit to warrant a higher price. However, most previous analyses did not fully consider possible cross‐protection by the bivalent vaccine and focused on high‐income countries. This study projected the health and economic tradeoffs of using either vaccine in low‐ and middle‐income countries, incorporating recent data on bivalent cross‐protection and Gavi‐negotiated vaccine prices. Although the nonavalent HPV vaccine was projected to avert more cases of cervical cancer, the bivalent vaccine, with an assumed high and long‐lasting cross‐protective efficacy, would be cost‐effective for nearly half of Gavi‐eligible countries. The human papillomavirus (HPV) vaccines may provide some level of cross-protection against high-risk HPV genotypes not directly targeted by the vaccines. We evaluated the long-term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vaccine in the context of 48 Gavi-eligible countries. We used a multi-modeling approach to compare the bivalent with or without cross-protection and the nonavalent HPV vaccine. The optimal, that is, most cost-effective, vaccine was the vaccine with an incremental cost-effectiveness ratio below the per-capita gross domestic product (GDP) for each country. By 2100 and assuming 70% HPV vaccination coverage, a bivalent vaccine without cross-protection, a bivalent vaccine with favorable cross-protection and the nonavalent vaccine were projected to avert 14.9, 17.2 and 18.5 million cumulative cases of cervical cancer across all 48 Gavi-eligible countries, respectively. The relative value of the bivalent vaccine compared to the nonavalent vaccine increased assuming a bivalent vaccine conferred high cross-protection. For example, assuming a cost-effectiveness threshold of per-capita GDP, the nonavalent vaccine was optimal in 83% (n = 40) of countries if the bivalent vaccine did not confer cross-protection; however, the proportion of countries decreased to 63% (n = 30) if the bivalent vaccine conferred high cross-protection. For lower cost-effectiveness thresholds, the bivalent vaccine was optimal in a greater proportion of countries, under both cross-protection assumptions. Although the nonavalent vaccine is projected to avert more cases of cervical cancer, the bivalent vaccine with favorable cross-protection can prevent a considerable number of cases and would be considered a high-value vaccine for many Gavi-eligible countries. The human papillomavirus (HPV) vaccines may provide some level of cross-protection against high-risk HPV genotypes not directly targeted by the vaccines. We evaluated the long-term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vaccine in the context of 48 Gavi-eligible countries. We used a multi-modeling approach to compare the bivalent with or without cross-protection and the nonavalent HPV vaccine. The optimal, that is, most cost-effective, vaccine was the vaccine with an incremental cost-effectiveness ratio below the per-capita gross domestic product (GDP) for each country. By 2100 and assuming 70% HPV vaccination coverage, a bivalent vaccine without cross-protection, a bivalent vaccine with favorable cross-protection and the nonavalent vaccine were projected to avert 14.9, 17.2 and 18.5 million cumulative cases of cervical cancer across all 48 Gavi-eligible countries, respectively. The relative value of the bivalent vaccine compared to the nonavalent vaccine increased assuming a bivalent vaccine conferred high cross-protection. For example, assuming a cost-effectiveness threshold of per-capita GDP, the nonavalent vaccine was optimal in 83% (n = 40) of countries if the bivalent vaccine did not confer cross-protection; however, the proportion of countries decreased to 63% (n = 30) if the bivalent vaccine conferred high cross-protection. For lower cost-effectiveness thresholds, the bivalent vaccine was optimal in a greater proportion of countries, under both cross-protection assumptions. Although the nonavalent vaccine is projected to avert more cases of cervical cancer, the bivalent vaccine with favorable cross-protection can prevent a considerable number of cases and would be considered a high-value vaccine for many Gavi-eligible countries.The human papillomavirus (HPV) vaccines may provide some level of cross-protection against high-risk HPV genotypes not directly targeted by the vaccines. We evaluated the long-term health and economic impacts of routine HPV vaccination using either the nonavalent HPV vaccine or the bivalent HPV vaccine in the context of 48 Gavi-eligible countries. We used a multi-modeling approach to compare the bivalent with or without cross-protection and the nonavalent HPV vaccine. The optimal, that is, most cost-effective, vaccine was the vaccine with an incremental cost-effectiveness ratio below the per-capita gross domestic product (GDP) for each country. By 2100 and assuming 70% HPV vaccination coverage, a bivalent vaccine without cross-protection, a bivalent vaccine with favorable cross-protection and the nonavalent vaccine were projected to avert 14.9, 17.2 and 18.5 million cumulative cases of cervical cancer across all 48 Gavi-eligible countries, respectively. The relative value of the bivalent vaccine compared to the nonavalent vaccine increased assuming a bivalent vaccine conferred high cross-protection. For example, assuming a cost-effectiveness threshold of per-capita GDP, the nonavalent vaccine was optimal in 83% (n = 40) of countries if the bivalent vaccine did not confer cross-protection; however, the proportion of countries decreased to 63% (n = 30) if the bivalent vaccine conferred high cross-protection. For lower cost-effectiveness thresholds, the bivalent vaccine was optimal in a greater proportion of countries, under both cross-protection assumptions. Although the nonavalent vaccine is projected to avert more cases of cervical cancer, the bivalent vaccine with favorable cross-protection can prevent a considerable number of cases and would be considered a high-value vaccine for many Gavi-eligible countries.
Author	Portnoy, Allison Sy, Stephen Regan, Catherine Kim, Jane J. Campos, Nicole G. Burger, Emily A.
Author_xml	– sequence: 1 givenname: Emily A. orcidid: 0000-0002-6657-5849 surname: Burger fullname: Burger, Emily A. email: eburger@hsph.harvard.edu organization: University of Oslo – sequence: 2 givenname: Allison orcidid: 0000-0002-8467-1324 surname: Portnoy fullname: Portnoy, Allison organization: Center for Health Decision Science – sequence: 3 givenname: Nicole G. orcidid: 0000-0002-0840-4339 surname: Campos fullname: Campos, Nicole G. organization: Center for Health Decision Science – sequence: 4 givenname: Stephen surname: Sy fullname: Sy, Stephen organization: Center for Health Decision Science – sequence: 5 givenname: Catherine surname: Regan fullname: Regan, Catherine organization: Center for Health Decision Science – sequence: 6 givenname: Jane J. surname: Kim fullname: Kim, Jane J. organization: Center for Health Decision Science
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32706907$$D View this record in MEDLINE/PubMed
BookMark	eNp1kc9u1DAQxi1URLeFAy-ALHGBQ1r_SdYxN7SCtqgSHApXy55Mul459hInRb3xCIhH5Ekw3a2EKjhZ4_l9n2bmOyIHMUUk5DlnJ5wxceo3cCKlkPIRWXCmVcUEbw7IovRYpbhcHpKjnDeMcd6w-gk5lEKxpWZqQX6u1illH6_ptEaatpMfbKDnn77QGwvgI76hV6WxRhumNfXD1sJEbewoQopp8FC4MBdlf2dQBrPlA-MOcn5f_GWYqY-0bumZvfG_vv_A4K-9C0ghzXEaPean5HFvQ8Zn-_eYfH7_7mp1Xl1-PLtYvb2sQDIpK22lbJG7hjnQCqDT0gkpYAm8c4KpXgJKDk1TC9e61tbKSttK7KGzTGmUx-TVznc7pq8z5skMPgOGYCOmORtRCyX0UvC2oC8foJs0j7FMVyjFWdM2WhfqxZ6a3YCd2Y7lmOOtub92AU53AIwp5xF7A36yk09lceuD4cz8ydOUPM1dnkXx-oHi3vRf7N79mw94-3_QXHxY7RS_AXZrr60
CitedBy_id	crossref_primary_10_1016_j_ypmed_2021_106662 crossref_primary_10_1080_21645515_2023_2295992 crossref_primary_10_1016_j_ypmed_2021_106688 crossref_primary_10_3390_diseases12080189 crossref_primary_10_3390_vaccines12060689 crossref_primary_10_3390_vaccines8040717 crossref_primary_10_1016_j_intimp_2024_113272 crossref_primary_10_1016_j_ijporl_2022_111423 crossref_primary_10_1016_j_mbs_2024_109247 crossref_primary_10_1016_j_vaccine_2021_11_041 crossref_primary_10_3390_vaccines12050548 crossref_primary_10_1002_pds_70222 crossref_primary_10_1186_s12889_024_17697_6 crossref_primary_10_1177_10732748241285184 crossref_primary_10_3390_ijms22179143 crossref_primary_10_1016_j_medmic_2025_100135 crossref_primary_10_1038_s41598_024_51594_7 crossref_primary_10_1093_heapol_czab052 crossref_primary_10_1136_bmjgh_2021_006940 crossref_primary_10_3389_fphar_2023_1181919 crossref_primary_10_1186_s12905_024_03113_z
Cites_doi	10.1056/NEJMoa061760 10.1016/j.pvr.2015.05.003 10.1016/j.jval.2016.02.017 10.1038/nrdp.2016.86 10.1080/21645515.2016.1140288 10.1136/bmjopen-2016-015048 10.1016/j.vaccine.2014.06.038 10.1093/jnci/djv086 10.1016/j.vaccine.2018.04.061 10.1136/bmjopen-2017-020484 10.1093/infdis/jiy067 10.1093/aje/kwu159 10.1002/ijc.28541 10.1007/s40273-017-0606-1 10.1093/heapol/czx166 10.1016/j.vaccine.2011.01.001 10.1002/ijc.31823 10.1093/jnci/djaa010 10.1016/S1473-3099(17)30468-1 10.1056/NEJMoa1405044 10.3322/caac.21492 10.1002/ijc.27485 10.1002/ijgo.12773 10.1016/S1470-2045(18)30836-2 10.1016/S1473-3099(12)70187-1 10.4161/hv.29532 10.1016/S2214-109X(15)00069-8 10.1016/S2468-2667(16)30019-6
ContentType	Journal Article
Copyright	2020 The Authors. published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. 2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: 2020 The Authors. published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. – notice: 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. – notice: 2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	24P AAYXX CITATION NPM 7T5 7TO 7U9 H94 K9. 7X8
DOI	10.1002/ijc.33233
DatabaseName	Wiley Online Library Open Access CrossRef PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic
DatabaseTitleList	CrossRef PubMed MEDLINE - Academic AIDS and Cancer Research Abstracts
Database_xml	– sequence: 1 dbid: 24P name: Wiley Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1097-0215
EndPage	940
ExternalDocumentID	32706907 10_1002_ijc_33233 IJC33233
Genre	article Journal Article
GrantInformation_xml	– fundername: Bill and Melinda Gates Foundation funderid: OPP1160242 – fundername: Bill and Melinda Gates Foundation grantid: OPP1160242
GroupedDBID	--- -~X .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X NPM 7T5 7TO 7U9 H94 K9. 7X8
ID	FETCH-LOGICAL-c3033-9a338e1b50bc97ccd93b232c6c1db207f3ce31c5542b8b8a47a3a83efcda079e3
IEDL.DBID	24P
ISSN	0020-7136 1097-0215
IngestDate	Fri Jul 11 10:00:15 EDT 2025 Sat Nov 29 14:31:27 EST 2025 Thu Apr 03 07:24:28 EDT 2025 Tue Nov 18 21:50:45 EST 2025 Sat Nov 29 03:46:32 EST 2025 Wed Jan 22 16:31:59 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	low- and middle-income countries vaccines cervical cancer human papillomavirus
Language	English
License	Attribution 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3033-9a338e1b50bc97ccd93b232c6c1db207f3ce31c5542b8b8a47a3a83efcda079e3
Notes	Funding information Bill and Melinda Gates Foundation, Grant/Award Number: OPP1160242 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-0840-4339 0000-0002-6657-5849 0000-0002-8467-1324
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.33233
PMID	32706907
PQID	2471058599
PQPubID	105430
PageCount	9
ParticipantIDs	proquest_miscellaneous_2427296218 proquest_journals_2471058599 pubmed_primary_32706907 crossref_citationtrail_10_1002_ijc_33233 crossref_primary_10_1002_ijc_33233 wiley_primary_10_1002_ijc_33233_IJC33233
PublicationCentury	2000
PublicationDate	15 February 2021
PublicationDateYYYYMMDD	2021-02-15
PublicationDate_xml	– month: 02 year: 2021 text: 15 February 2021 day: 15
PublicationDecade	2020
PublicationPlace	Hoboken, USA
PublicationPlace_xml	– name: Hoboken, USA – name: United States – name: Hoboken
PublicationTitle	International journal of cancer
PublicationTitleAlternate	Int J Cancer
PublicationYear	2021
Publisher	John Wiley & Sons, Inc Wiley Subscription Services, Inc
Publisher_xml	– name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc
References	2015; 1 2017; 7 2015; 3 2016; 19 2007 2015; 107 2012; 12 2019; 144 2019; 145 2014; 134 2016; 12 2015; 68 2007; 356 2015; 372 2018; 8 2012; 131 2016; 1 2016; 2 2019; 20 2017; 17 2020 2018; 217 2019 2014; 180 2017 2013 2018; 33 2011; 29 2014; 32 2018; 36 2014; 10 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 Australian Cancer Incidence and Mortality (AIHW) (e_1_2_10_30_1) 2013 World Health Organization (e_1_2_10_4_1) 2017 e_1_2_10_2_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_33_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_31_1 World Health Organization & International Agency for Research on Cancer (e_1_2_10_5_1) 2007 (e_1_2_10_10_1) 2020 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1
References_xml	– volume: 2 year: 2016 article-title: Carcinogenic human papillomavirus infection publication-title: Nat Rev Dis Primers – volume: 68 start-page: 394 year: 2015 end-page: 424 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. publication-title: CA: a cancer journal for clinicians – volume: 145 start-page: 40 issue: 1 year: 2019 end-page: 46 article-title: The cost‐effectiveness of implementing HPV testing for cervical cancer screening in El Salvador publication-title: Int J Gynaecol Obstet – volume: 36 start-page: 4823 issue: 32 year: 2018 end-page: 4829 article-title: Health and economic benefits of single‐dose HPV vaccination in a Gavi‐eligible country publication-title: Vaccine – year: 2007 – start-page: djz222 year: 2020 article-title: Efficacy of the AS04‐adjuvanted HPV‐16/18 vaccine: pooled analysis of the Costa Rica vaccine and PATRICIA randomized controlled trials publication-title: J Natl Cancer Inst – volume: 107 start-page: djv086 issue: 6 year: 2015 article-title: US assessment of HPV types in cancers: implications for current and 9‐valent HPV vaccines publication-title: J Natl Cancer Inst – volume: 32 start-page: 5087 issue: 39 year: 2014 end-page: 5097 article-title: Efficacy of the HPV‐16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial publication-title: Vaccine – volume: 3 start-page: e712 issue: 11 year: 2015 end-page: e723 article-title: Disability weights for the global burden of disease 2013 study publication-title: Lancet Glob Health – volume: 7 issue: 6 year: 2017 article-title: Cost‐effectiveness of HPV‐based cervical cancer screening in the public health system in Nicaragua publication-title: BMJ Open – volume: 134 start-page: 2264 issue: 9 year: 2014 end-page: 2268 article-title: Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccine publication-title: Int J Cancer – year: 2020 article-title: Durability of cross‐protection by different schedules of the bivalent HPV vaccine: the CVT trial publication-title: J Natl Cancer Inst – volume: 17 start-page: 1293 issue: 12 year: 2017 end-page: 1302 article-title: Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7‐year cross‐sectional study publication-title: Lancet Infect Dis – volume: 144 start-page: 687 issue: 4 year: 2019 end-page: 696 article-title: Health impact of delayed implementation of cervical cancer screening programs in India: a modeling analysis publication-title: Int J Cancer – volume: 217 start-page: 1579 issue: 10 year: 2018 end-page: 1589 article-title: High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women publication-title: J Infect Dis – volume: 19 start-page: 929 issue: 8 year: 2016 end-page: 935 article-title: Country‐level cost‐effectiveness thresholds: initial estimates and the need for further research publication-title: Value Health – volume: 10 start-page: 2147 issue: 8 year: 2014 end-page: 2162 article-title: Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination publication-title: Hum Vaccin Immunother – volume: 180 start-page: 545 issue: 5 year: 2014 end-page: 555 article-title: An updated natural history model of cervical cancer: derivation of model parameters publication-title: Am J Epidemiol – volume: 1 start-page: 38 year: 2015 end-page: 58 article-title: When and how often to screen for cervical cancer in three low‐ and middle‐income countries: a cost‐effectiveness analysis publication-title: Papillomavirus Res – volume: 372 start-page: 711 issue: 8 year: 2015 end-page: 723 article-title: A 9‐valent HPV vaccine against infection and intraepithelial neoplasia in women publication-title: N Engl J Med – volume: 12 start-page: 781 issue: 10 year: 2012 end-page: 789 article-title: Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis publication-title: Lancet Infect Dis – volume: 8 issue: 6 year: 2018 article-title: Community‐based HPV self‐collection versus visual inspection with acetic acid in Uganda: a cost‐effectiveness analysis of the ASPIRE trial publication-title: BMJ Open – volume: 33 start-page: 204 issue: 2 year: 2018 end-page: 214 article-title: Thresholds for decision‐making: informing the cost‐effectiveness and affordability of rotavirus vaccines in Malaysia publication-title: Health Policy Plan – year: 2017 – year: 2019 – volume: 36 start-page: 509 issue: 5 year: 2018 end-page: 522 article-title: Cost‐effectiveness thresholds: the past, the present and the future publication-title: Pharmacoeconomics – volume: 20 start-page: 394 issue: 3 year: 2019 end-page: 407 article-title: Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study publication-title: Lancet Oncol – volume: 356 start-page: 1928 issue: 19 year: 2007 end-page: 1943 article-title: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases publication-title: N Engl J Med – volume: 29 start-page: 2011 issue: 11 year: 2011 end-page: 2014 article-title: HPV16/18 L1 VLP vaccine induces cross‐neutralizing antibodies that may mediate cross‐protection publication-title: Vaccine – volume: 1 start-page: e66 issue: 2 year: 2016 end-page: e75 article-title: Cost‐effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis publication-title: Lancet Public Health – volume: 12 start-page: 1363 issue: 6 year: 2016 end-page: 1372 article-title: The impact and cost‐effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model publication-title: Hum Vaccin Immunother – volume: 131 start-page: 2349 issue: 10 year: 2012 end-page: 2359 article-title: Human papillomavirus types in 115,789 HPV‐positive women: a meta‐analysis from cervical infection to cancer publication-title: Int J Cancer – year: 2013 – ident: e_1_2_10_7_1 doi: 10.1056/NEJMoa061760 – ident: e_1_2_10_20_1 doi: 10.1016/j.pvr.2015.05.003 – ident: e_1_2_10_33_1 doi: 10.1016/j.jval.2016.02.017 – start-page: djz222 year: 2020 ident: e_1_2_10_10_1 article-title: Efficacy of the AS04‐adjuvanted HPV‐16/18 vaccine: pooled analysis of the Costa Rica vaccine and PATRICIA randomized controlled trials publication-title: J Natl Cancer Inst – ident: e_1_2_10_2_1 doi: 10.1038/nrdp.2016.86 – ident: e_1_2_10_17_1 doi: 10.1080/21645515.2016.1140288 – ident: e_1_2_10_23_1 doi: 10.1136/bmjopen-2016-015048 – ident: e_1_2_10_6_1 doi: 10.1016/j.vaccine.2014.06.038 – volume-title: Weekly epidemiological record. Contract No.: 19 year: 2017 ident: e_1_2_10_4_1 – ident: e_1_2_10_31_1 doi: 10.1093/jnci/djv086 – ident: e_1_2_10_18_1 doi: 10.1016/j.vaccine.2018.04.061 – ident: e_1_2_10_24_1 doi: 10.1136/bmjopen-2017-020484 – ident: e_1_2_10_14_1 doi: 10.1093/infdis/jiy067 – ident: e_1_2_10_19_1 doi: 10.1093/aje/kwu159 – ident: e_1_2_10_15_1 doi: 10.1002/ijc.28541 – ident: e_1_2_10_34_1 doi: 10.1007/s40273-017-0606-1 – ident: e_1_2_10_32_1 doi: 10.1093/heapol/czx166 – ident: e_1_2_10_8_1 – ident: e_1_2_10_12_1 doi: 10.1016/j.vaccine.2011.01.001 – ident: e_1_2_10_21_1 doi: 10.1002/ijc.31823 – ident: e_1_2_10_35_1 doi: 10.1093/jnci/djaa010 – ident: e_1_2_10_26_1 – volume-title: IARC Monographs on the evaluation of carcinogenic risks to humans year: 2007 ident: e_1_2_10_5_1 – ident: e_1_2_10_13_1 doi: 10.1016/S1473-3099(17)30468-1 – ident: e_1_2_10_9_1 – volume-title: Cervical screening in Australia 2010–2011. Cancer series 76. Cat no. CAN 72. Cancer series year: 2013 ident: e_1_2_10_30_1 – ident: e_1_2_10_28_1 doi: 10.1056/NEJMoa1405044 – ident: e_1_2_10_3_1 doi: 10.3322/caac.21492 – ident: e_1_2_10_25_1 doi: 10.1002/ijc.27485 – ident: e_1_2_10_22_1 doi: 10.1002/ijgo.12773 – ident: e_1_2_10_36_1 doi: 10.1016/S1470-2045(18)30836-2 – ident: e_1_2_10_11_1 doi: 10.1016/S1473-3099(12)70187-1 – ident: e_1_2_10_27_1 doi: 10.4161/hv.29532 – ident: e_1_2_10_29_1 doi: 10.1016/S2214-109X(15)00069-8 – ident: e_1_2_10_16_1 doi: 10.1016/S2468-2667(16)30019-6
SSID	ssj0011504
Score	2.4767876
Snippet	The human papillomavirus (HPV) vaccines may provide some level of cross‐protection against high‐risk HPV genotypes not directly targeted by the vaccines. We... The human papillomavirus (HPV) vaccines may provide some level of cross-protection against high-risk HPV genotypes not directly targeted by the vaccines. We...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	932
SubjectTerms	Cancer Cancer vaccines Cervical cancer Cervix GDP Genotypes Gross Domestic Product Human papillomavirus Immunization low‐ and middle‐income countries Medical research Vaccines
Title	Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi‐eligible countries
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.33233 https://www.ncbi.nlm.nih.gov/pubmed/32706907 https://www.proquest.com/docview/2471058599 https://www.proquest.com/docview/2427296218
Volume	148
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011504 issn: 0020-7136 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7xqBAXoA_aLRSZqodeAomdrGM4oS0LRRStqoL2FtnORA2iWcTCnvsTqv5EfgljJxuKWqRKXKI8JrZljz3f-PENwIdcJ3EhNAaJlRiQhVCBybXb78AL27U5pj7G0tmxPDlJh0M1mIHd6VmYmh-inXBzPcOP166DazPevicNLc_tlhBciFmYjyKRurgNPB60SwiEdBoK5jAgT6w7pRUK-Xb760Nj9BfCfAhYvcXpLz-prCuw1ABNtldrxnOYweoFLHxpltJfwu_e99HITRQwgoBsRCPHDxI_HJyxibZOZIeRCrH6nCSrD1MyXeUMm6PMzPGE05-FT6AiRE8vyIR5IVM2D38kOGZlxeKUHehJefvzl98LbS6Q-XAVzmN_Baf9_W-9w6AJ0BBY4WLAKU0OLkYmCY1V0tpcCUMIjdo4yg0PZSEsisgSYuEmNamOpRY6FVjYXIdSoViFOSoevgEmDPIo10VcSBc7mKtEoepyhTpBwmyiAx-nLZXZhr3cBdG4yGreZZ5RHWe-jjvwvhW9rCk7_iW0Pm3urOm144yTpQ7Jf1KqA5vtZ-pvbhFFVzi6cTKc_JEuIaMOvK7VpM1FcOmInyUV1mvD49lnn496_ubt_4uuwSJ3G2pcNJpkHeaur27wHTyzk-tyfLXhlZ-ucphuwPynr_3T4zsCEAnc
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VFkEvtDy7bQGDOHAJzdrJOq64oC3bLWxXFWqr3iLbmYigkq267Z77Eyp-Ir-EseMNVICExC2PcWzZM5lv_PgG4FWh06QUGqPUSozIQ6jIFNrtd-Cl7dkCM59j6Xgkx-Ps5EQdLMDb-VmYhh-inXBzluH_187A3YT01k_W0OqLfSMEF-IWLCWkRqTfSzufBkejdhWBwE5gYY4jCsZ6c2ahmG-1hW_6o99A5k3M6p3OYOX_mrsK9wLYZO8a7bgPC1g_gDv7YTn9IXzrf55M3GQBIxjIJvT3-Eriw4NjNtPWiWwzUiPWnJVkzYFKpuuCYTjOzBxXOJUs_QdqQvX0gNyYFzJVuPnlg1NW1SzJ2K6eVd-vrv1-aHOKzKescFH7IzgavD_sD6OQpCGywuWBU5qCXOyaNDZWSWsLJQyhNBrnbmF4LEthUXQtoRZuMpPpRGqhM4GlLXQsFYrHsEjNwzVgwiDvFrpMSunyB3OVKlQ9rlCnSLhNdOD1fKhyGxjMXSKN07zhXuY59XHu-7gDL1vRs4a2409Cm_PxzoPlTnNO3jqmGEqpDrxoX5PNuYUUXePk0slwikl6hI468KTRk7YWwaUjf5bUWK8Of68-3_vQ9xfr_y76HO4OD_dH-Whv_HEDlrnbYOOy06SbsHhxfolP4badXVTT82fBFn4AHp0M2g
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6VFFVceD8CBQziwGXpxt6N14gLSgkthChCtOpt5cesulXZVE2bMz8B8RP5JYy9zkIFSEjc9jF-yPZ4vvHjG4BnTudZJTQmuZWYkIVQiXHan3fglR1ah0WIsbQ_kdNpcXCgZmvwanUXpuWH6BbcvGaE-dorOJ64ausna2h9ZF8IwYW4BOuZDyLTg_Xtj-O9SbeLQGAnsjCnCTljwxWzUMq3usQX7dFvIPMiZg1GZ3zt_6p7Ha5GsMlet6PjBqxhcxM2PsTt9FvwbXQ4n_vFAkYwkM1p9vhM4juzfbbU1ou8ZDSMWHtXkrUXKpluHMN4nZl5rnBKWYUMGkL19IHMWBAydXz5JcMFqxuWFeytXtbfv3wN56HNMbIQssJ77bdhb_zm02gniUEaEit8HDilycnFgclTY5W01ilhCKVRPw-c4amshEUxsIRauClMoTOphS4EVtbpVCoUd6BH1cN7wIRBPnC6yirp4wdzlSukblWocyTcJvrwfNVVpY0M5j6QxnHZci_zktq4DG3ch6ed6ElL2_Enoc1Vf5dRcxclJ2udkg-lVB-edL9J5_xGim5wfu5lOPkkQ0JHfbjbjpOuFMGlJ3-WVNkwHP5efLn7bhQe7v-76GPYmG2Py8nu9P0DuML9-RofnCbfhN7Z6Tk-hMt2eVYvTh9FVfgBl1UMVQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Choosing+the+optimal+HPV+vaccine%3A+The+health+impact+and+economic+value+of+the+nonavalent+and+bivalent+HPV+vaccines+in+48+Gavi%E2%80%90eligible+countries&rft.jtitle=International+journal+of+cancer&rft.au=Burger%2C+Emily+A.&rft.au=Portnoy%2C+Allison&rft.au=Campos%2C+Nicole+G.&rft.au=Sy%2C+Stephen&rft.date=2021-02-15&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=148&rft.issue=4&rft.spage=932&rft.epage=940&rft_id=info:doi/10.1002%2Fijc.33233&rft.externalDBID=10.1002%252Fijc.33233&rft.externalDocID=IJC33233
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon